

This article was downloaded by:

On: 28 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Phosphorus, Sulfur, and Silicon and the Related Elements

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713618290>

### Synthesis and Anti-HIV-1 Reverse Transcriptase Activity of Triphosphates of Penciclovir and $\beta$ -D-Dioxolane-Guanine

Zbigniew J. Lesnikowski<sup>ab</sup>; Amy S. Juodawlkis<sup>ab</sup>; Robert M. Lloyd Jr.<sup>ab</sup>; Chunk K. Chu<sup>ab</sup>; Raymond F. Schinazi<sup>ab</sup>

<sup>a</sup> Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine and VA Medical Center, Decatur, Georgia <sup>b</sup> College of Pharmacy, University of Georgia, Athens, Georgia

**To cite this Article** Lesnikowski, Zbigniew J. , Juodawlkis, Amy S. , Lloyd Jr., Robert M. , Chu, Chunk K. and Schinazi, Raymond F.(1996) 'Synthesis and Anti-HIV-1 Reverse Transcriptase Activity of Triphosphates of Penciclovir and  $\beta$ -D-Dioxolane-Guanine', *Phosphorus, Sulfur, and Silicon and the Related Elements*, 111: 1, 83

**To link to this Article:** DOI: 10.1080/10426509608054712

**URL:** <http://dx.doi.org/10.1080/10426509608054712>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.


## SYNTHESIS AND ANTI-HIV-1 REVERSE TRANSCRIPTASE ACTIVITY OF TRIPHOSPHATES OF PENCICLOVIR AND $\beta$ -D-DIOXOLANE-GUANINE

ZBIGNIEW J. LESNIKOWSKI,<sup>1</sup> AMY S. JUODAWLKIS,<sup>1</sup> ROBERT M. LLOYD, JR.,<sup>1</sup>  
 CHUNK K. CHU<sup>2</sup> AND RAYMOND F. SCHINAZI<sup>1\*</sup>

<sup>1</sup>Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University  
 School of Medicine and VA Medical Center, Decatur, Georgia 30033; and College of  
 Pharmacy, University of Georgia, Athens, Georgia 30602,<sup>2</sup> USA.

**Abstract** The synthesis of *R*- and *S*-9-(4-Hydroxy-3-hydroxymethyl-but-1-yl)guanine (PCV) and (-)- $\beta$ -D-dioxolane-guanine (DXG) triphosphate and their enzyme inhibitory activity is described.

Penciclovir (PCV) and (-)- $\beta$ -D-dioxolane-guanine (DXG) are selective antiviral agents against certain herpesviruses and human immunodeficiency viruses (HIV), respectively. The triphosphate forms inhibit viral replication by acting as substrates for viral polymerases.<sup>1</sup> To test the activity of nucleotide analogues against HIV-1 reverse transcriptase (RT) *in vitro*, the suitable triphosphates were synthesized.



Phosphorylation of *O*-monoiso-butyl-PCV (*R*-, *S*- or racemic form) with 2-chloro-4*H*-1,2,3-dioxaphosphorin-4-one followed by reaction with tri-*n*-butylammonium pyrophosphate, oxidation,<sup>2</sup> and removal of isobutyl protection produced the desired PCV-triphosphates. Similarly DXG-triphosphate was synthesized. Enzymatic assays using a poly(rC)<sub>n</sub>.oligo(dG)<sub>12-18</sub> template primer revealed potent activity of PCV- and DXG-triphosphates against HIV-1 RT.

**ACKNOWLEDGMENTS.**  
 Supported by the NIH grant

RO1-AI 25899 and the Department of Veterans Affairs.

### REFERENCES.

1. R.F. SCHINAZI, *Perspective in Drug Discovery and Design*, 1, 1, 180 (1993).
2. J. LUDWIG, F. ECKSTEIN, *J. Org. Chem.*, 54, 631 (1989).